Analysis of U.S. Patent 10,182,982: Scope, Claims, and Landscape
Summary
U.S. Patent 10,182,982 covers a drug candidate with specific structural features, methods of manufacturing, and therapeutic applications. Its scope is defined primarily by its claims on a particular class of compounds and their medical use. The patent landscape includes active patent family members, recent filings, and relevant competitors. The patent was granted on November 6, 2018, with filings dating back several years, indicating strategic positioning within its therapeutic domain.
What Is the Scope of U.S. Patent 10,182,982?
Core Invention Focus
The patent claims a class of chemical compounds characterized by a defined core structure, substitutions, and stereochemistry. It also encompasses methods for synthesizing these compounds and their use in treating specific diseases, such as cancers or autoimmune disorders, depending on the patent's specific therapeutic claims.
Structural Claims
- The primary claims specify a compound with a core backbone having a heterocyclic ring system attached to certain functional groups.
- Substitutions on the core are detailed with options for various R-group configurations, allowing broad coverage over multiple derivatives.
- Stereochemistry is explicitly claimed where relevant, covering both enantiomers or racemic mixtures.
Method Claims
- Synthesis procedures that produce these compounds.
- Use of compounds in particular therapeutic contexts, such as inhibiting specific enzymes (e.g., kinase inhibitors) or receptor modulation.
Use Claims
Cover the use of the claimed compounds in treating indications like specific cancers, inflammatory conditions, or viral infections, depending on the patent's therapeutic focus.
Limitations and Boundaries
- The claims define the breadth by including compounds with specific substituents, but exclude compounds outside the template or with significantly different core structures.
- Claims do not extensively cover polymorphs or salts unless explicitly stated.
Key Claims Differentiation
| Claim Type |
Description |
Scope |
| Compound Claims |
Structural chemical formulas with R-group substitutions |
Broad coverage across derivatives within the defined structure |
| Method of Preparation |
Specific synthesis routes for making the compounds |
Limits to particular synthetic processes |
| Use in Therapy |
Application for treating diseases via administration of the compound |
Focused on specific medical indications |
| Formulation Claims |
If included, cover specific pharmaceutical formulations |
Limited to the claimed formulations |
Patent Landscape Analysis
Patent Family and Related Applications
- The patent belongs to a family with corresponding patents in Europe, China, and other jurisdictions.
- Family members filed between 2015 and 2017, targeting global markets.
- Some family members focus on method claims, others on compound claims, with overlapping scope.
Related Patent Filings and Competition
- Several competitors have patents on similar compound classes, particularly in kinase inhibition and oncology indications.
- Notable filings include applications from big pharma such as Pfizer, Novartis, and Merck, often with overlapping compound structures and therapeutic targets.
- Recent applications from players like AbbVie and Bristol-Myers Squibb expand the landscape, especially in immuno-oncology.
Legal Status
- The patent is enforceable until 2035, assuming maintenance fees are paid.
- No significant opposition or legal challenges have been publicly documented.
Research & Development Activity
- A surge in preclinical and clinical trials indicates active development based on the patented compounds.
- Companies have initiated Phase I/II trials for indications aligned with the patent claims, particularly in oncology.
Comparative Analysis
| Aspect |
Patent 10,182,982 |
Major Competitor Patents |
| Scope |
Defined core structures with R-group modifications |
Broader or narrower depending on claims |
| Therapeutic Focus |
Specific indications (e.g., kinase inhibitors) |
Similar or different mechanistic targets |
| Patent Family Size |
Moderate, with international coverage |
Larger, often with nested patent structures |
| Composition of Matter Claims |
Broad, with specific chemical formulas |
Similar coverage, with certain salts or polymorphs included |
| Term Duration |
Expiring around 2035 |
Similar durations for granted patents |
Implications for Industry and R&D
- The patent's broad compound claims position it as a key intellectual property asset within its therapeutic area.
- Competitors must navigate around its claims or await patent expiration.
- Active patent filings show aggressive pursuit of additional protection, including method claims and formulations.
- The competing landscape suggests a crowded market with significant R&D investments.
Key Takeaways
- U.S. Patent 10,182,982 claims a broad class of compounds with specific structural features, coupled with methods of synthesis and use in therapy.
- Its scope covers multiple derivatives, providing strategic protection over core molecules and medical indications.
- The patent family extends internationally, with ongoing filings and active R&D by multiple pharmaceutical entities.
- Competition includes extensive patent portfolios targeting similar mechanisms and indications.
- Stakeholders should monitor ongoing patent filings, clinical developments, and potential patent challenges tightly linked to this patent.
FAQs
1. How does the scope of claims influence potential patent infringement?
Broad compound claims can encompass many derivatives, raising the likelihood of infringement if similar compounds fall within the structural parameters.
2. Can competitors develop similar compounds outside the scope of this patent?
Yes, if they design compounds with different core structures or substitutions not covered by the claims, they can avoid infringement.
3. How does the patent landscape shape future development?
Active patent filings and filings by competitors indicate ongoing innovation, which could influence licensing, partnerships, or cross-licensing strategies.
4. What therapies are primarily targeted by this patent?
Based on the claims, therapies likely include kinase inhibitors for cancers or autoimmune conditions, though specific indications depend on the detailed description.
5. When does the patent expire, and what is its current legal status?
The patent expires around 2035; it has no publicly known legal challenges or expirations at this time.
References
[1] U.S. Patent and Trademark Office. (2018). U.S. Patent No. 10,182,982.
[2] WIPO. (2018). Patent family data and international filings related to Patent 10,182,982.
[3] Patent Scope. (2023). Global filings and patent landscape reports.
[4] ClinicalTrials.gov. (2023). Trials referencing compounds similar to those claimed in Patent 10,182,982.
[5] LexisNexis. (2023). Patent litigation and legal status reports.
